In addition to the contract, EIT is currently finalizing an action plan with HCA leadership to understand the economic impact this novel technology will have on fusion rates, implant costs and the need for high cost osteobiologics.
Roswell, GA (PRWEB) December 11, 2017
Emerging Implant Technologies GmbH (EIT), a German medical device manufacturer exclusively focused on creating innovative technologies for spinal application by utilizing additive manufacturing, announces that it has now successfully completed the contracting process with HealthTrust related to an HCA contract and is now able to offer all interbody products for Cervical, ALIF, TLIF and PLIF procedures in the 177 hospitals and 119 freestanding surgery centers located throughout the United States.
EIT Cellular Titanium® is a 3D printed porous titanium structure that has been designed according to scientific insights on ideal pore shape and size to optimize cell proliferation and bone ingrowth.
With the addition of this contract, EIT is poised to continue its aggressive growth pattern in the United States. EIT believes that this will create more unique opportunities to work with HCA surgeons to evaluate and take advantage of the validated structure and many other unique features that differentiate EIT from other 3D printed products.
The contract approval was pursued and successfully completed by Ortho Sales Partners. Josh Sandberg, President of OSP said, “This is a huge milestone that we have been able to help achieve at an unusually early stage in EIT’s development. That is a credit to the strength of this product offering and we are excited about the opportunity to work with HCA facilities in helping them lower the overall cost of these spine procedures.”
“EIT´s goal is to improve spine care using the advantages of 3D printing technology and cope with given pricing and reimbursement structures. We are delighted that HCA/HealthTrust is interested in working with EIT. This will help us to get quicker market access in the United States” said Guntmar Eisen, cofounder and CEO of EIT.
In addition to the contract, EIT is currently finalizing an action plan with HCA leadership to understand the economic impact this novel technology will have on fusion rates, implant costs and the need for high cost osteobiologics. Further details of this proposal will be announced at a later time.
EIT is the first medical device manufacturer to exclusively focus on implants for spinal alignment, that are designed according to latest published science on optimal bone ingrowth in porous titanium scaffolds and produced with additive manufacturing methods. EIT was founded in 2014 by Hans Eekhof and Guntmar Eisen.
The EIT implants are made of EIT Cellular Titanium®, that addresses the clinical shortcomings of the current cage designs and materials (non-fusion, biocompatibility, subsidence, migration and imaging distortion), thereby obtaining very promising fusion results and improved clinical outcome due to the qualities of the porous 3-D printing of titanium. The highly porous titanium scaffold ensures extensive bone ingrowth as a result of its specific design and elasticity close to the cancellous bone. Due to its unique design with a porosity of 80% the EIT implants ensure uncompromised imaging on X-ray and MRI and enabling excellent follow up on defining bone ingrowth and fusion with CT.
A complete portfolio of Smart Spinal Implants™ based on EIT Cellular Titanium® is available for the cervical and lumbar spine, with an extensive choice in footprint sizes, heights and lordosis angles to support the recreation of sagittal balance and alignment. Since 2014 over 12.000 EIT cases have been performed in over 15 markets globally.